IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 72.85

Change

+0.18 (+0.25)%

Market Cap

N/A

Volume

0.06M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-03 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.65 (+0.44%)

USD 37.71B
FHLC Fidelity® MSCI Health Care In..

+0.11 (+0.16%)

USD 2.77B
FXH First Trust Health Care AlphaD..

-1.11 (-1.04%)

USD 1.05B
XHE SPDR® S&P Health Care Equipme..

-1.29 (-1.46%)

USD 0.20B
IDNA iShares Genomics Immunology an..

-0.58 (-2.58%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-1.34 (-4.28%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

-1.53 (-1.57%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.49 (-1.69%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-2.27 (-3.68%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-1.16 (-5.71%)

USD 6.67M

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.85% 100% F 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.85% 100% F 91% A-
Trailing 12 Months  
Capital Gain 6.75% 86% B+ 61% D-
Dividend Return 1.36% 88% B+ 23% F
Total Return 8.11% 86% B+ 54% F
Trailing 5 Years  
Capital Gain 42.20% 76% C+ 66% D+
Dividend Return 9.24% 95% A 25% F
Total Return 51.44% 76% C+ 62% D
Average Annual (5 Year Horizon)  
Capital Gain 3.97% 48% F 47% F
Dividend Return 5.37% 57% F 44% F
Total Return 1.39% 100% F 34% F
Risk Return Profile  
Volatility (Standard Deviation) 15.27% 71% C- 66% D+
Risk Adjusted Return 35.16% 67% D+ 49% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike